Product logins

Find logins to all Clarivate products below.


Hospital-Treated Infections | TreatmentTrends | US | 2015

Hospital emergency departments (EDs) are sites where the majority of patients with serious, acute bacterial infections initially seek medical care. As such, these sites often represent the initial treatment setting, where patients receive the first dose of antibiotic(s) and are triaged for possible hospital admission or subsequent therapy in the outpatient setting. Therefore, EDs play an important role in initial treatment/brand selection. This report examines the current trends in management and antibiotic treatment of patients presenting to EDs with bacterial infections, and it examines their management and treatment through hospital inpatient and/or outpatient care following discharge. The report evaluates prescribing practices and guidelines in the ER, in the inpatient setting, and upon patient discharge.

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…